Nitric Oxide-sensitive Guanylyl Cyclase is the Only Nitric Oxide Receptor Mediating Platelet Inhibition
Overview
Affiliations
Background: The nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling cascade is involved in the precise regulation of platelet responses. NO released from the endothelium is known to activate NO-sensitive guanylyl cyclase (NO-GC) in platelets. By the generation of cGMP and subsequent activation of cGMP-dependent protein kinase (PKG), NO-GC mediates the reduction of the intracellular calcium and inhibits platelet adhesion and aggregation. However, NO has been postulated to influence these platelet functions also via cGMP-independent mechanisms.
Objective: We studied the effect of NO on platelets lacking NO-sensitive guanylyl cyclase with regards to aggregation, adhesion, calcium mobilization and bleeding time.
Methods And Results: Here, we show that NO signaling leading to inhibition of agonist-induced platelet aggregation is totally abrogated in platelets from mice deficient in NO-GC (GCKO). Even at millimolar concentrations none of the several different NO donors inhibited collagen-induced aggregation of GCKO platelets. In addition, NO neither affected adenosine 5'-diphosphate (ADP)-induced adhesion nor thrombin-induced calcium release in GCKO platelets. Although the NO-induced cGMP signal transduction was totally abrogated cyclic adenosine monophosphate (cAMP) signaling was still functional; however, cGMP/cAMP crosstalk was disturbed on the level of phosphodiesterase type 3 (PDE3). These in vitro data are completed by a reduced bleeding time indicating the lack of NO effect in vivo.
Conclusions: We conclude that NO-GC is the only NO receptor in murine platelets mediating the inhibition of calcium release, adhesion and aggregation: lack of the enzyme leads to disturbance of primary hemostasis.
The Cortisol Effect on the NO/cGMP Pathway.
Signorello M, Leoncini G Int J Mol Sci. 2025; 26(4).
PMID: 40003888 PMC: 11855650. DOI: 10.3390/ijms26041421.
Li S, Yang S, Sun X, Ma T, Zheng Y, Liu X Bioengineering (Basel). 2025; 12(2).
PMID: 40001710 PMC: 11851545. DOI: 10.3390/bioengineering12020191.
Ma C, Wang C, Dai T, Chen T, Zhu W Int J Ophthalmol. 2024; 17(5):869-876.
PMID: 38766331 PMC: 11074200. DOI: 10.18240/ijo.2024.05.11.
Platelet Cyclic GMP Levels Are Reduced in Patients with Primary Aldosteronism.
Sala C, Rescaldani M, Gherbesi E, Bolla G, Cuspidi C, Ruscica M J Clin Med. 2023; 12(22).
PMID: 38002693 PMC: 10672647. DOI: 10.3390/jcm12227081.
The Triple Crown: NO, CO, and HS in cancer cell biology.
Oza P, Kashfi K Pharmacol Ther. 2023; 249:108502.
PMID: 37517510 PMC: 10529678. DOI: 10.1016/j.pharmthera.2023.108502.